$62.41
0[0.00%]
Last update: 5:41PM Get Real Time Here
Exact Sciences
(NASDAQ:EXAS)Exact Sciences Stock (NASDAQ:EXAS), Analyst Ratings, Price Targets, Predictions
Exact Sciences Corp has a consensus price target of $82.71, established from looking at the 76 latest analyst ratings. The last 3 analyst ratings were released from Citigroup, Canaccord Genuity, and Benchmark on April 3, 2024, February 22, 2024, and January 2, 2024. With an average price target of $93.67 between Citigroup, Canaccord Genuity, and Benchmark, there's an implied 50.08% upside for Exact Sciences Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
Canaccord Genuity
Benchmark
Guggenheim
Wolfe Research
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Exact Sciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/03/2024 | EXAS | Buy Now | Exact Sciences | $62.41 | 60.23% | Citigroup | Patrick Donnelly | → $100 | Maintains | Buy | Get Alert |
| 02/22/2024 | EXAS | Buy Now | Exact Sciences | $62.41 | 44.21% | Canaccord Genuity | Kyle Mikson | $100 → $90 | Maintains | Buy | Get Alert |
| 01/02/2024 | EXAS | Buy Now | Exact Sciences | $62.41 | 45.81% | Benchmark | Bruce Jackson | → $91 | Upgrade | Hold → Buy | Get Alert |
| 12/14/2023 | EXAS | Buy Now | Exact Sciences | $62.41 | 44.21% | Guggenheim | Subbu Nambi | → $90 | Initiates | → Buy | Get Alert |
| 12/13/2023 | EXAS | Buy Now | Exact Sciences | $62.41 | — | Wolfe Research | Doug Schenkel | — | Initiates | → Outperform | Get Alert |
| 11/03/2023 | EXAS | Buy Now | Exact Sciences | $62.41 | 44.21% | Goldman Sachs | Matthew Sykes | $100 → $90 | Maintains | Buy | Get Alert |
| 10/16/2023 | EXAS | Buy Now | Exact Sciences | $62.41 | 28.18% | Piper Sandler | David Westenberg | $90 → $80 | Maintains | Overweight | Get Alert |
| 10/10/2023 | EXAS | Buy Now | Exact Sciences | $62.41 | 44.21% | Piper Sandler | David Westenberg | → $90 | Upgrade | Neutral → Overweight | Get Alert |
| 09/28/2023 | EXAS | Buy Now | Exact Sciences | $62.41 | 32.99% | Bernstein | Eve Burstein | → $83 | Initiates | → Outperform | Get Alert |
| 08/08/2023 | EXAS | Buy Now | Exact Sciences | $62.41 | 44.21% | Piper Sandler | David Westenberg | $80 → $90 | Maintains | Neutral | Get Alert |
| 08/03/2023 | EXAS | Buy Now | Exact Sciences | $62.41 | 76.25% | Jefferies | Brandon Couillard | $100 → $110 | Maintains | Buy | Get Alert |
| 08/02/2023 | EXAS | Buy Now | Exact Sciences | $62.41 | 44.21% | Credit Suisse | Dan Leonard | $75 → $90 | Maintains | Neutral | Get Alert |
| 08/02/2023 | EXAS | Buy Now | Exact Sciences | $62.41 | 93.88% | Baird | Catherine Schulte | $99 → $121 | Maintains | Outperform | Get Alert |
| 08/02/2023 | EXAS | Buy Now | Exact Sciences | $62.41 | — | Benchmark | Bruce Jackson | — | Downgrade | Buy → Hold | Get Alert |
| 07/24/2023 | EXAS | Buy Now | Exact Sciences | $62.41 | 76.25% | Goldman Sachs | Matthew Sykes | $85 → $110 | Maintains | Buy | Get Alert |
| 07/21/2023 | EXAS | Buy Now | Exact Sciences | $62.41 | 76.25% | Goldman Sachs | Matthew Sykes | $85 → $110 | Maintains | Buy | Get Alert |
| 06/23/2023 | EXAS | Buy Now | Exact Sciences | $62.41 | 84.27% | Canaccord Genuity | Kyle Mikson | $92 → $115 | Maintains | Buy | Get Alert |
| 06/22/2023 | EXAS | Buy Now | Exact Sciences | $62.41 | 108.3% | Citigroup | Patrick Donnelly | $100 → $130 | Maintains | Buy | Get Alert |
| 06/22/2023 | EXAS | Buy Now | Exact Sciences | $62.41 | 53.82% | Benchmark | Bruce Jackson | → $96 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Exact Sciences (EXAS)?
The latest price target for Exact Sciences (NASDAQ: EXAS) was reported by Citigroup on April 3, 2024. The analyst firm set a price target for $100.00 expecting EXAS to rise to within 12 months (a possible 60.23% upside). 29 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Exact Sciences (EXAS)?
The latest analyst rating for Exact Sciences (NASDAQ: EXAS) was provided by Citigroup, and Exact Sciences maintained their buy rating.
When was the last upgrade for Exact Sciences (EXAS)?
The last upgrade for Exact Sciences Corp happened on January 2, 2024 when Benchmark raised their price target to $91. Benchmark previously had a hold for Exact Sciences Corp.
When was the last downgrade for Exact Sciences (EXAS)?
The last downgrade for Exact Sciences Corp happened on August 2, 2023 when Benchmark changed their price target from N/A to N/A for Exact Sciences Corp.
When is the next analyst rating going to be posted or updated for Exact Sciences (EXAS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Exact Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Exact Sciences was filed on April 3, 2024 so you should expect the next rating to be made available sometime around April 3, 2025.
Is the Analyst Rating Exact Sciences (EXAS) correct?
While ratings are subjective and will change, the latest Exact Sciences (EXAS) rating was a maintained with a price target of $0.00 to $100.00. The current price Exact Sciences (EXAS) is trading at is $62.41, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.